Accuray, which offers an FDA-approved robotic radiosurgery system to treat solid tumors, priced its IPO of 16 million shares at $18, a 20% premium to the midpoint of its originally proposed $14 to $16 range, on Wednesday night. The pricing came in at the high end of the revised $17 to $18 range, which was changed earlier in the day. The firm also sold more shares than initially planned, with 6 million coming from insiders and 10 million from Accuray. JP Morgan and UBS Investment Bank were joint book runners on the deal. The stock is expected to begin trading on the NASDAQ under the ticker ARAY on Thursday.
